Cancer Research Cancer Health Disparities Conference 2009  Cancer Genome no Abstract
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Foltz, G.
Right arrow Articles by Madan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Foltz, G.
Right arrow Articles by Madan, A.
[Cancer Research 66, 6665-6674, July 1, 2006]
© 2006 American Association for Cancer Research


Cell, Tumor, and Stem Cell Biology

Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma

Greg Foltz1,3, Gi-Yung Ryu1, Jae-Geun Yoon1, Timothy Nelson1, Jessica Fahey1, Amanda Frakes1, Hwahyung Lee1, Lorie Field1, Kaitlin Zander1, Zita Sibenaller1, Timothy C. Ryken1, Rajeev Vibhakar2, Leroy Hood3 and Anup Madan1,3

1 Neurogenomic Research Laboratory, Department of Neurosurgery; 2 Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa; and 3 Institute for Systems Biology, Seattle, Washington

Requests for reprints: Anup Madan, Neurogenomics Research Laboratory, Department of Neurosurgery, University of Iowa Carver College of Medicine, 200 B Eckstein Medical Research Building, Iowa City, IO 52242. Phone: 319-3358491; Fax: 319-3358078; E-mail: anup-madan{at}uiowa.edu.

Promoter hypermethylation and histone deacetylation are common epigenetic mechanisms implicated in the transcriptional silencing of tumor suppressor genes in human cancer. We treated two immortalized glioma cell lines, T98 and U87, and 10 patient-derived primary glioma cell lines with trichostatin A (TSA), a histone deacetylase inhibitor, or 5-aza-2'-deoxycytidine (5-AzaC), a DNA methyltransferase inhibitor, to comprehensively identify the cohort of genes reactivated through the pharmacologic reversal of these distinct but related epigenetic processes. Whole-genome microarray analysis identified genes induced by TSA (653) or 5-AzaC treatment (170). We selected a subset of reactivated genes that were markedly induced (greater than two-fold) after treatment with either TSA or 5-AzaC in a majority of glioma cell lines but not in cultured normal astrocytes. We then characterized the degree of promoter methylation and transcriptional silencing of selected genes in histologically confirmed human tumor and nontumor brain specimens. We identified two novel brain expressed genes, BEX1 and BEX2, which were silenced in all tumor specimens and exhibited extensive promoter hypermethylation. Viral-mediated reexpression of either BEX1 or BEX2 led to increased sensitivity to chemotherapy-induced apoptosis and potent tumor suppressor effects in vitro and in a xenograft mouse model. Using an integrated approach, we have established a novel platform for the genome-wide screening of epigenetically silenced genes in malignant glioma. This experimental paradigm provides a powerful new method for the identification of epigenetically silenced genes with potential function as tumor suppressors, biomarkers for disease diagnosis and detection, and therapeutically reversible modulators of critical regulatory pathways important in glioma pathogenesis. (Cancer Res 2006; 66(13): 6665-74)




This article has been cited by other articles:


Home page
J Biomol ScreenHome page
C.-L. Chang
Genome-Wide Oligonucleotide Microarray Analysis of Gene-Expression Profiles of Taiwanese Patients with Anaplastic Astrocytoma and Glioblastoma Multiforme
J Biomol Screen, October 1, 2008; 13(9): 912 - 921.
[Abstract] [PDF]


Home page
Mol Cancer ResHome page
K. J. Dudley, K. Revill, P. Whitby, R. N. Clayton, and W. E. Farrell
Genome-Wide Analysis in a Murine Dnmt1 Knockdown Model Identifies Epigenetically Silenced Genes in Primary Human Pituitary Tumors
Mol. Cancer Res., October 1, 2008; 6(10): 1567 - 1574.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. A. Payne, S. Maleki, M. Messina, M. G. O'Sullivan, G. Stone, N. R. Hall, J. F. Parkinson, H. R. Wheeler, R. J. Cook, M. T. Biggs, et al.
Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma
Mol. Cancer Ther., October 1, 2008; 7(10): 3420 - 3428.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Naderi, A. E. Teschendorff, J. Beigel, M. Cariati, I. O. Ellis, J. D. Brenton, and C. Caldas
BEX2 Is Overexpressed in a Subset of Primary Breast Cancers and Mediates Nerve Growth Factor/Nuclear Factor-{kappa}B Inhibition of Apoptosis in Breast Cancer Cell Lines
Cancer Res., July 15, 2007; 67(14): 6725 - 6736.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
R. Vibhakar, G. Foltz, J.-g. Yoon, L. Field, H. Lee, G.-y. Ryu, J. Pierson, B. Davidson, and A. Madan
Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma
Neuro-oncol, April 1, 2007; 9(2): 135 - 144.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.